Citations

Mayo Clinic

Clear

15 citation(s) found for "Grach, Stephanie L".

Severe and very severe ME/CFS – when healthcare is out of reach: A qualitative study
Hackl, Verena , Hainzl, Astrid, Wojczewski, Silvia , Maukner, Anna, Mair, Lucia, Saugstad, Ola Didrik , Grach, Stephanie L. , Hoffmann, Kathryn

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-11494085/v1 Get It

Abstract Severe and very severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) causes profound functional impairment and substantial multisystem manifestations, leaving many home- or bed-bound, highly dependent on family/lay caregivers, and often invisible to healthcare. This qualitative study explored healthcare experiences, unmet needs, and barriers to healthcare access among people with severe and very severe ME/CFS, their family/lay caregivers, and healthcare professionals in Austria. Adapted narrative and semi-structured interviews were conducted alongside focus groups and expert interviews with healthcare professionals. Data were analysed using qualitative thematic analysis. Our findings suggest that knowledge gaps, absent or limited transportability, and insufficiently adapted healthcare services restricted access to necessary care, and could even make healthcare itself a risk for deterioration. Family/Lay caregivers frequently assumed coordinative, nursing, and medical responsibilities in the absence of accessible professional support. Improving provision for this population requires models designed around the functional capacities and individual needs of people with severe and very severe ME/CFS, including home-based and outreach care, telemedicine, multidisciplinary coordination, adapted routine and emergency care, and ME/CFS-specific professional education. Future studies should evaluate such models and strengthen research inclusion, particularly of people with very severe ME/CFS.
The Use of a Handheld Non-Invasive Vagal Nerve Stimulation (nVNS) Device for the Treatment of Long COVID: A Pilot Randomized Controlled Trial
Ganesh, Ravindra , Yadav, Siddhant, Croghan, Ivana T. , Hanson, Jennifer, Erickson, Megan, Fokken, Shawn, Seegmiller, Sara, Grach, Stephanie L. , Gilman, Elizabeth A. , Mueller, Michael , Croghan, Ivana T , Grach, Stephanie L , Gilman, Elizabeth A , Hurt, Ryan T. , Mueller, Michael R , Ganesh, Ravindra , Fokken, Shawn C. , Schroeder, Darrell R. , Hanson, Jennifer L., Seegmiller, Sara

Journal of Primary Care & Community Health | July 25, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261473073 | PMID 42501005 Get It

Objectives Long-term symptoms following infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2), termed post-acute sequelae of SARS-CoV-2 infection (PASC) or Long COVID (LC), persist beyond 90 days and may impact at least 10% of patients with acute infection. The exact cause of LC remains unknown, but several theories include persistent viral particles, immune dysfunction, and autonomic nervous system (ANS) imbalance, particularly involving the vagus nerve. Given the role of the vagus nerve in inflammation regulation, vagal nerve stimulation (VNS) is being explored as a treatment option. The present study aimed to evaluate the feasibility, safety, and exploratory effects of a handheld external transcutaneous cervical non-invasive VNS (tcVNS) on the primary endpoint of Post-COVID Functional Status (PCFS) grade, alongside secondary outcomes such as LC-related fatigue and other symptoms. Methods Participants from our Post COVID Care Clinic were randomized into treatment (tcVNS treatments two minutes, three times a day) and control (no VNS) groups for a study period of 12 weeks. Participants completed validated questionnaires, PET-CT scans, and inflammatory cytokines at baseline and 12 weeks. Results All randomized patients (8 tcVNS, 10 control) completed the 12-week study. Participants randomized to tcVNS were observed to have improvements in PHQ-9, PROMIS-F, and COMPASS-31 when compared to controls, but these differences were not statistically significant. Cortisol and DHEA were also observed to increase less in the tcVNS group when compared to the control group, but these changes were also not statistically significant. Conclusions tcVNS was well tolerated and may be a promising therapeutic approach for LC, a chronic disease with no approved treatments and very low rates of complete recovery.
Persistent Cerebral 18-FDG PET Changes in Patients With Long COVID Presenting With Fatigue and Post Exertional Malaise
Ganesh, Ravindra , Nair, Kaavya, Grach, Stephanie L. , Croghan, Ivana T. , Yadav, Siddhant, Mueller, Michael , Hurt, Ryan T. , Mueller, Michael R , Ganesh, Ravindra , Grach, Stephanie L , Nair, Kaavya

Journal of Primary Care & Community Health | June 9, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.1177/21501319261458748 | PMID 42259512 Get It

Objective Long COVID (LC) refers to the long-term symptoms occurring after SARS-CoV-2 infection and resolution of the initial disease prodrome. While LC is increasingly recognized, knowledge about its biomarkers is still limited. This study examines imaging findings in 18 F-FDG PET-CT scans in 40 patients with LC from an academic LC Clinic, for potential imaging biomarkers. Methods This study included patients aged 18 and older with confirmed positive SARS-CoV-2 PCR test and at least 28 days post-symptom onset. 18 F-FDG PET-CT scans were performed, and brain metabolic activity was compared to a control database to generate Z-scores. Participants were grouped based on their clinical phenotype and Z-scores of different brain regions were analyzed using t-tests. Results The study group was mainly female (70%), with a median age of 53 years, and predominantly non-Hispanic White (90%). Most had pre-existing conditions such as gastrointestinal, cardiovascular, endocrine, and psychiatric disorders. The findings showed significant cerebral hypometabolism in 29 patients with fatigue and post-exertional malaise (PEM), particularly in the left sensorimotor cortex (p=0.0253) and bilateral primary visual cortex (right: p=0.0096, left: p=0.0016), which persisted up to two years after infection. Conclusions In summary, this study identified persistent cerebral hypometabolism in LC patients, especially those with fatigue with PEM, up to two years post-infection. These results suggest that 18 F-FDG PET-CT could be a valuable tool for diagnosing and managing LC. Further research is essential to confirm these findings and improve treatment strategies for patients with LC.
Improving Diagnostic Accuracy of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Through a Point-of-Care Clinical Algorithm
Seltzer, Jaime, Grach, Stephanie L. , Eggers, Scott D.Z. , Redetzke, Melissa M., Mau, Katie, Chon, Tony Y. , Seltzer, J. L. , Seltzer, Jaime , Eggers, Scott D , Mau, Katie J, Grach, Stephanie L , Ganesh, Ravindra

International Journal of Environmental Research and Public Health | April 6, 2026 | Volume: 23 | Issue: 4 | Pages: 460

10.3390/ijerph23040460 | PMID 42074399 Get It

Despite the increasing prevalence and median severity of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), medical education on the disease is scant, leading to a diagnostic crisis in which the majority of people with ME/CFS are undiagnosed. We created a care process algorithm in AskMayoExpert accessible to all Mayo Clinic medical providers as a source for information on diagnosis and management of ME/CFS. To evaluate whether the algorithm was associated with improved diagnostic accuracy, we compared concordance before versus after the algorithm was introduced, where concordance was defined as agreement between an appropriately coded referral to Mayo Clinic’s Chronic Fatigue Specialty Clinic and the specialty clinic with an expert diagnosis of ME/CFS. Referrals to the Chronic Fatigue Specialty Clinic increased overall and were more likely to show concordance between specialist diagnosis and referral after the introduction of the ME/CFS AskMayoExpert algorithm. Particularly in diseases that are prevalent and poorly understood, a point-of-care clinical tool may offer just-in-time opportunities to improve diagnosis and management.
Long COVID Syndrome and Associated New Daily Persistent Headache ( NDPH ) Presenting With Crossed Clonus Response
Wetmore, Emma , Wetmore, Emma , Grach, Stephanie, Grach, Stephanie L. , Boes, Christopher J. , Lanzino, Giuseppe , Kissoon, Narayan

Clinical Case Reports | March 20, 2026 | Volume: 14 | Issue: 3 | Pages: No page available

10.1002/ccr3.72386 | PMID 42016647 Get It

ABSTRACT Evaluating patients following a COVID‐19 infection with multiple chronic, progressive symptoms can be challenging, but easy to navigate by using the temporal profile obtained from the clinical history, findings from the neurological exam, and screening for red flag symptoms.
A Signal for Voice and Speech Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Grach, Stephanie L. , Seltzer, J. L. , Orbelo, Diana M. , Seltzer, Jaime , Grach, Stephanie L , Orbelo, Diana

Journal of Clinical Medicine | July 8, 2025 | Volume: 14 | Issue: 14 | Pages: 4847

10.3390/jcm14144847 | PMID 40725538 Get It

Background/Objectives: Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may report abnormalities in voice and speech; however, no formal research has been conducted in this area. Methods: An online mixed-methods survey was completed by 685 people with ME/CFS. A total of 302 respondents completed the qualitative component (44.09%). Questions assessed disease experience with ME/CFS and post-exertional malaise without prompting on specific symptoms. Within the qualitative results, a search of the terms “speech, voice,” “words,” and “speak” was conducted. Results: Excluding neurocognitive associations, colloquial phrases, and “speech therapy,” there were 38 mentions of the terms in the context of voice or speech changes across 28 unique qualitative survey responses (9.27%). Conclusions: A notable portion of respondents reported voice or speech changes when responding to open-ended qualitative questions about their disease experience. More research is needed regarding the implications of voice and speech anomalies in ME/CFS pathology and disease monitoring.
Low Dose Rapamycin Alleviates Clinical Symptoms of Fatigue and PEM in ME/CFS Patients via Improvement of Autophagy
Ruan, Brian T., Bulbule, Sarojini , Reyes, Amy, Chheda, Bela, Bateman, Lucinda , Bell, Jennifer , Yellman, Braydon, Berner, Jon , Peterson, Daniel L., Kaufman, David L. , Gottschalk, C. Gunnar , Grach, Stephanie, Roy, Avik , Ruan, Brian T. , Gile, Brooke, Reyes, Amy, Bell, Jennifer, Yellman, Brayden P., Grach, Stephanie L.

No container title available | June 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6596158/v1 | PMID 40502741 Get It

Abstract Background: mTOR activation is associated with chronic inflammation in ME/CFS. Previous studies have shown that sustained mTOR activation can cause chronic muscle fatigue by inhibiting ATG13-mediated autophagy. This highlights the pivotal role of mTOR in the pathogenesis of ME/CFS. Methods: We conducted a decentralized, uncontrolled trial of rapamycin in 86 patients with ME/CFS to evaluate its safety and efficacy. Low-dose rapamycin (6 mg/week) was administered, and core ME/CFS symptoms were assessed on days 30 (T1), 60 (T2), and 90 (T3). Plasma levels of autophagy metabolites, such as pSer258-ATG13 and BECLIN-1, were measured and correlated with clinical outcomes, specifically MFI. Results: Rapamycin (6 mg/week) was tolerated without any SAEs. Of the 40 patients, 29 (72.5%) showed strong recovery in PEM, fatigue, and OI, along with improvements in MFI fatigue domains and SF-36 aspects. High levels of BECLIN-1 were detected in T3. Plasma pSer258-ATG13 levels were strongly downregulated at T1. Spearman’s correlation analysis indicated an association between autophagy impairment and reduced activity. Conclusions: Low-dose rapamycin effectively reduced PEM and other key symptoms in patients with ME/CFS, as measured by BAS, SSS, MFI, and SF-36. Future studies should encompass dose optimization and develop a diagnostic tool to identify responders with mTOR-mediated autophagy disruption.
Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders
Darakjian, Ashley A. , Bhutani, Mira, Fairweather, DeLisa , Kocsis, S , Fliess, Jessica J. , Khatib, Sami , Weigel, Gabe J , McCabe, Elizabeth J , Balamurugan, Varsini, Perona, Evan E , Gehin, Jessica M. , Jain, Angita , Sledge, Hanna, Hodge, David O. , Rozen, Todd D. , Soyer, Ozan, Cheung, Joseph , Shirey, David, Gajarawala, Shilpa , Munipalli, Bala , Weigel, G. , Kocsis, S Christian, Whelan, Emily R. , Rozen, Todd D , Farraye, Francis A , Cheung, Joseph , Grach, Stephanie L , Gajarawala, Shilpa , Munipalli, Bala , Shufelt, Chrisandra L , Knight, Dacre R T , Bruno, Katelyn A , Fairweather, DeLisa , Bhutani, Mira, Farraye, Francis A. , Soyer, Ozan, Grach, Stephanie L. , Shufelt, Chrisandra , Bruno, Katelyn A.

Rheumatology Advances in Practice | December 10, 2024 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/rap/rkae134 | PMID 39660107 Get It

Abstract Objectives Patients with hypermobile Ehlers–Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) experience a wide array of symptoms and system disorders. This study aimed to identify whether differences occurred in 115 self-reported symptoms and comorbidities in patients diagnosed with hEDS or HSD. Methods In this study we analysed self-reported data from an EDS Clinic intake questionnaire in patients diagnosed with hEDS, HSD or no hypermobile conditions. Results From 1 November 2019 to 7 March 2024, the EDS Clinic saw 2088 patients. Using the 2017 diagnostic criteria, 66.5% were diagnosed with HSD (n = 1389), 20.3% with hEDS (n = 423), 10.6% with historic HSD (H-HSD) or localized HSD (L-HSD) (n = 256) (hypermobile controls) and 2.6% were not diagnosed with hEDS, HSD, H-HSD or L-HSD (n = 55) (controls). Symptoms/comorbidities that occurred with high prevalence in both hEDS and HSD included joint pain (hEDS 82.0%, HSD 88.9%), allergy (hEDS 77.0%, HSD 77.0%), subluxations (hEDS 71.2%, HSD 72.6%), brain fog (hEDS 70.0%, HSD 74.7%), headache (hEDS 68.1%, HSD 69.1%), anxiety (hEDS 60.3%, HSD 69.3%), depression (hEDS 52.2%, HSD 58.0%), migraine (hEDS 53.7%, HSD 52.5%), nausea (hEDS 54.6%, HSD 59.5%) and constipation (hEDS 53.0%, HSD 57.2%). In contrast, 9/115 (8%) symptoms/comorbidities were self-reported significantly more often in hEDS but 42/115 (37%) in HSD. hEDS patients reported more symptoms that suggest a defect in collagen, such as dislocation, hernias and rectal prolapse, while HSD patients reported more joint, muscle, allergy, neurological, gastrointestinal, sleep and psychological symptoms/comorbidities. Conclusion Although we found an overlap in some symptoms and comorbidities self-reported by hEDS/HSD patients, such as allergy/atopy, headache/migraine and gastrointestinal symptoms, our findings suggest key differences exist between the two diagnoses, suggesting that hEDS and HSD may be distinct conditions.
Nerve pathology and cutaneous features of acute rheumatoid vasculitis
Jones, Felipe J.S. , Daley, Catherine, Grach, Stephanie L. , Mason, Thomas G. , Pinto, Marcus Vinícius , Pinto, Marcus V , Jones, Felipe J S , Grach, Stephanie L , Mason, Thomas G

Rheumatology Advances in Practice | October 4, 2024 | Volume: 8 | Issue: 4 | Pages: No page available

10.1093/rap/rkae124 | PMID 39465119 Get It

Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey
Yadav, Siddhant, Schroeder, Darrell R. , Croghan, Ivana T. , Mueller, Michael , Grach, Stephanie L. , Aakre, Christopher A. , Gilman, Elizabeth A. , Stephenson, Christopher R. , Overgaard, Joshua , Collins, Nerissa M. , Lawson, Donna K. , Thompson, Ann M., Natividad, Lasonya T., Hurt, Ryan T. , Croghan, Ivana T , Grach, Stephanie L , Mohamed Elfadil, Osman , Ganesh, Ravindra , Schroeder, Darrell , Thompson, Ann M., Elfadil, Osman Mohamed , Ganesh, Ravindra

Journal of Primary Care & Community Health | May 30, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241258671 | PMID 38813984 Get It

Background: In addition to the morbidity and mortality associated with acute infection, COVID-19 has been associated with persistent symptoms (>30 days), often referred to as Long COVID (LC). LC symptoms often cluster into phenotypes, resembling conditions such as fibromyalgia, postural orthostatic tachycardiac syndrome (POTS), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). LC clinics have been established to best address the needs of LC patients and continuity of care. We developed a cross-sectional survey to assess treatment response through our LC Clinic (LCC). Methods: A 25-question survey (1-10 Likert scale) was expert- and content-validated by LCC clinicians, patients, and patient advocates. The survey assessed LC symptoms and the helpfulness of different interventions, including medications and supplements. A total of 852 LCC patients were asked to complete the survey, with 536 (62.9%) responding. Results: The mean time from associated COVID-19 infection to survey completion was 23.2 ± 6.4 months. The mean age of responders was 52.3 ± 14.1 (63% females). Self-reported symptoms were all significantly improved ( P < .001) from the initial visit to the LCC (baseline) to the time of the follow-up survey. However, only 4.5% (24/536) of patients rated all symptoms low (1-2) at the time of the survey, indicating low levels of full recovery in our cohort. The patients rated numerous interventions as being helpful, including low-dose naltrexone (45/77; 58%), vagal nerve stimulation (18/34; 53%), and fisetin (28/44; 64%). Conclusions: Patients report general improvements in symptoms following the initial LCC visit, but complete recovery rates remain low at 23.2 ± 6.4 months.